Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (“FDZJ”, “the Company”), established in November 1996, is located in Zhangjiang Hi-Tech park, Pudong, Shanghai. The shareholders of the Company are well-known companies such as Shanghai Pharmaceuticals Holding Co., Ltd.
 
FDZJ is mainly engaged in the innovative research and development (R&D), production and marketing of biopharmaceuticals. Since its establishment, with the ultimate goal of staying as an innovator and a leader in the bio-pharmaceutical industry, FDZJ has been committed to exploring the unmet needs and deficiencies in clinical treatments as well as developing more effective treatments and medicines, so as to realize our mission of “The More We Explore, the Healthier Human Beings Will Be”. Currently, FDZJ has established multiple R&D platforms across various fields, including genetic engineering, photodynamic, nano and oral solid preparation. These platforms support treatments covering dermatological conditions, malignant tumors and autoimmune diseases, among others.

FDZJ has undertaken many R&D initiatives, including National Key Programs for Science and Technology Development, National Hi-tech R&D Program (“Program 863”), and Major New Drugs Innovation and Development. FDZJ has been recognized as a hi-tech enterprise since 1998. In August 2002, the Company was listed on the Growth Enterprise Market of the Stock Exchange of Hong Kong Limited (Stock Code: 8231) and transferred to the Main Board of the Stock Exchange in December 2013 (Stock Code: 1349). In June 2020, the Company was listed on the STAR Market of the Shanghai Stock Exchange (Stock Code: 688505). Thus, FDZJ became one of A+H listing companies.

Taizhou Fudan-Zhangjiang Pharmaceutical Co., Ltd., Fermovelty (Hong kong) Holdings Ltd and. Shanghai Tracing Bio-technology Co., Ltd. are the subsidiaries of FDZJ. The Group has rich human resource and strong technique power. About 1000 high-quality employees will lead the R&D of new drugs forward for the greater progress.